Literature DB >> 12371906

A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers.

Marina R Bergman1, Sunfa Cheng, Norman Honbo, Lucia Piacentini, Joel S Karliner, David H Lovett.   

Abstract

Enhanced synthesis of a specific matrix metalloproteinase, MMP-2, has been demonstrated in experimental models of ventricular failure and in cardiac extracts from patients with ischaemic cardiomyopathy. Cultured neonatal rat cardiac fibroblasts and myocytes were used to analyse the determinants of MMP-2 synthesis, including the effects of hypoxia. Culture of rat cardiac fibroblasts for 24 h in 1% oxygen enhanced MMP-2 synthesis by more than 5-fold and augmented the MMP-2 synthetic responses of these cells to endothelin-1, angiotensin II and interleukin 1beta. A series of MMP-2 promoter-luciferase constructs were used to map the specific enhancer element(s) that drive MMP-2 transcription in cardiac cells. Deletion studies mapped a region of potent transactivating function within the 91 bp region from -1433 to -1342 bp, the activity of which was increased by hypoxia. Oligonucleotides from this region were cloned in front of a heterologous simian-virus-40 (SV40) promoter and mapped the enhancer activity to a region between -1410 and -1362 bp that included a potential activating protein 1 (AP-1)-binding sequence, C(-1394)CTGACCTCC. Site-specific mutagenesis of the core TGAC sequence (indicated in bold) eliminated the transactivating activity within the -1410 to -1362 bp sequence. Electrophoretic mobility shift assays (EMSAs) using the -1410 to -1362 bp oligonucleotide and rat cardiac fibroblast nuclear extracts demonstrated specific nuclear-protein binding that was eliminated by cold competitor oligonucleotide, but not by the AP-1-mutated oligonucleotide. Antibody-supershift EMSAs of nuclear extracts from normoxic rat cardiac fibroblasts demonstrated Fra1 and JunB binding to the -1410 to -1362 bp oligonucleotide. Nuclear extracts isolated from hypoxic rat cardiac fibroblasts contained Fra1, JunB and also included FosB. Co-transfection of cardiac fibroblasts with Fra1-JunB and FosB-JunB expression plasmids led to significant increases in transcriptional activity. These studies demonstrate that a functional AP-1 site mediates MMP-2 transcription in cardiac cells through the binding of distinctive Fra1-JunB and FosB-JunB heterodimers. The synthesis of MMP-2 is widely considered, in contrast with many members of the MMP gene family, to be independent of the AP-1 transcriptional complex. This report is the first demonstration that defined members of the Fos and Jun transcription-factor families specifically regulate this gene under conditions relevant to critical pathophysiological processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12371906      PMCID: PMC1223099          DOI: 10.1042/BJ20020707

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

Review 1.  Infarct scar: a dynamic tissue.

Authors:  Y Sun; K T Weber
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

Review 2.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Authors:  W G Stetler-Stevenson
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

3.  Quick guide. Matrix metalloproteinases.

Authors:  L M Matrisian
Journal:  Curr Biol       Date:  2000-10-05       Impact factor: 10.834

Review 4.  Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.

Authors:  F G Spinale; M L Coker; B R Bond; J L Zellner
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

5.  Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

Authors:  J T Peterson; H Li; L Dillon; J W Bryant
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

Review 6.  The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression.

Authors:  M P Vincenti
Journal:  Methods Mol Biol       Date:  2001

Review 7.  Fos family members: regulation, structure and role in oncogenic transformation.

Authors:  E Tulchinsky
Journal:  Histol Histopathol       Date:  2000-07       Impact factor: 2.303

8.  Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C.

Authors:  L Piacentini; M Gray; N Y Honbo; J Chentoufi; M Bergman; J S Karliner
Journal:  J Mol Cell Cardiol       Date:  2000-04       Impact factor: 5.000

9.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

10.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

View more
  53 in total

1.  Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury.

Authors:  Rupak Mukherjee; Gregory P Colbath; Charles D Justus; James A Bruce; Claire M Allen; Kenneth W Hewett; J Philip Saul; Robert G Gourdie; Francis G Spinale
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

Review 2.  Matrix metalloproteinases: pathways of induction by bioactive molecules.

Authors:  Toshihiro Tsuruda; Lisa C Costello-Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 3.  Fetal hypoxia and programming of matrix metalloproteinases.

Authors:  Wenni Tong; Lubo Zhang
Journal:  Drug Discov Today       Date:  2011-09-18       Impact factor: 7.851

4.  Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.

Authors:  Rajeev Mahimkar; Anita Nguyen; Michael Mann; Che-Chung Yeh; Bo-Qing Zhu; Joel S Karliner; David H Lovett
Journal:  Cardiovasc Pathol       Date:  2008-10-01       Impact factor: 2.185

5.  Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK.

Authors:  Jalahalli M Siddesha; Anthony J Valente; Siva S V P Sakamuri; Tadashi Yoshida; Jason D Gardner; Naveen Somanna; Chiaki Takahashi; Makoto Noda; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2013-10-02       Impact factor: 5.000

6.  Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction.

Authors:  Hui-Zhong Zhou; Xiaokui Ma; Mary O Gray; Bo-qing Zhu; Anita P Nguyen; Anthony J Baker; Ursula Simonis; Gary Cecchini; David H Lovett; Joel S Karliner
Journal:  Biochem Biophys Res Commun       Date:  2007-04-23       Impact factor: 3.575

7.  The conversion of rapid TCCD nongenomic signals to persistent inflammatory effects via select protein kinases in MCF10A cells.

Authors:  Bin Dong; Fumio Matsumura
Journal:  Mol Endocrinol       Date:  2009-01-15

8.  A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion.

Authors:  Pavan Adiseshaiah; Michelle Vaz; Narsa Machireddy; Dhananjaya V Kalvakolanu; Sekhar P Reddy
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

9.  Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells.

Authors:  Shlomit Goldman; David H Lovett; Eliezer Shalev
Journal:  Reprod Biol Endocrinol       Date:  2009-05-09       Impact factor: 5.211

10.  Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts.

Authors:  Kirsten Riches; Michael E Morley; Neil A Turner; David J O'Regan; Stephen G Ball; Chris Peers; Karen E Porter
Journal:  J Mol Cell Cardiol       Date:  2009-06-11       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.